Article: Nicotinamide Riboside Protects Retinal Nerve Cells in Glaucoma: Preclinical Findings

PrevNext
Glaucoma Neurological Health Preclinical Sensory (Auditory/Optical)

Nicotinamide Riboside Protects Retinal Nerve Cells in Glaucoma: Preclinical Findings

Synopsis

Glaucoma causes progressive retinal ganglion cell (RGC) degeneration and vision loss, often associated with elevated intraocular pressure (IOP). This study tested whether oral administration of nicotinamide riboside (NR), an NAD+ precursor, could protect RGCs in a rat model of ocular hypertension induced by laser treatment. NR significantly increased retinal NAD+ levels and preserved optic nerve axons after three weeks of treatment. Morphometric analyses showed reduced axonal loss and increased neurofilament staining in NR-treated animals. NR also enhanced phosphorylation of AMP-activated protein kinase (p-AMPK) in optic nerves, suggesting improved energy metabolism. These results indicate that oral NR administration protects against glaucomatous RGC axonal degeneration, potentially via AMPK activation, and supports NR as a neuroprotective candidate for glaucoma.

Journal

Current Issues in Molecular Biology

Share

Read more

Cancer

Using Engineered Cancer Cells to Identify How Orphan Cytotoxins Work: Preclinical Findings

Synopsis Orphan cytotoxins are small molecules whose exact targets or mechanisms are unknown. Understanding how they work can reveal new research tools and potential therapies. To help identify th...

Read more
Cardiovascular Health

Nicotinamide Riboside and Nicotinamide Mononucleotide Prevent Oxidative Stress in Blood Vessel Cells From COVID-19 Patients: Preclinical Findings

SynopsisCOVID-19 is associated with vascular endothelial dysfunction, but mechanisms remain unclear. This study exposed human aortic endothelial cells (HAECs) to plasma from hospitalized COVID-19 p...

Read more